---
canonical_name: Andrographis
alternate_names: Andrographis paniculata, Kalmegh, King of Bitters, Chuan Xin Lian, Green Chiretta, Creat, Indian Echinacea, Sambiloto
canonical_topic: Andrographis for Health & Longevity
short_topic_lc: andrographis
creation_date: 2026-0715-0119
creator_ai_fullname: Opus 4.8
---

# Andrographis for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/15/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Andrographis paniculata, Kalmegh, King of Bitters, Chuan Xin Lian, Green Chiretta, Creat, Indian Echinacea, Sambiloto


## Motivation

<!-- This motivation section was written after the rest of the document was completed, so it reflects the full scope of the topic. -->

Andrographis (*Andrographis paniculata*, often called "King of Bitters") is a bitter-tasting herb from South and Southeast Asia. Its leaves have been used for centuries in traditional Indian and Chinese medicine to ease fevers, colds, and digestive complaints. The plant's most-studied active substance, andrographolide, is thought to work mainly by calming the body's inflammation signals and by nudging the immune system toward a balanced response.

Today the herb is widely sold as a supplement, most often to shorten common colds and to support the immune system through the winter season. Standardized extracts have been tested in dozens of small clinical trials, and one large pooled analysis of cold and flu studies found it eased cough and sore throat faster than a placebo. Interest has since broadened to joint comfort, blood-sugar balance, and general inflammation, which connects the herb to the wider goals of healthy aging.

This review examines what the evidence shows about Andrographis for people focused on long-term health and longevity. It weighs the benefits, the safety signals, sensible dosing, quality concerns, and the open questions that current research has yet to settle.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-quality, high-level overviews of Andrographis from clinical experts and the broader research literature.

<!-- A real-time web search was performed across the priority expert platforms (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com) and the general web for in-depth, topic-specific content on Andrographis. Chris Kresser and Life Extension had directly relevant material; no dedicated Andrographis content was found from Rhonda Patrick, Peter Attia, or Andrew Huberman. Systematic reviews, meta-analyses, encyclopedias, and forums were excluded. -->

* [The Top 20 Natural Remedies for Cold and Flu](https://chriskresser.com/the-top-20-natural-remedies-for-cold-and-flu/) - Chris Kresser

A practitioner overview that describes Andrographis as a primary herb for early cold and flu, including its evidence base and the practical timing and dosing that shape real-world use.

* [Common Cold](https://www.lifeextension.com/protocols/infections/common-cold) - Life Extension

An integrative protocol that situates Andrographis among evidence-based options for shortening respiratory infections, summarizing key trials and typical standardized-extract doses.

* [Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide](https://pubmed.ncbi.nlm.nih.gov/23634174/) - Jayakumar et al., 2013

A narrative review connecting the herb's traditional uses to its measured effects on inflammation, cardiovascular signaling, blood platelets, and fertility, giving a broad mechanistic map of andrographolide.

* [Andrographis paniculata (Burm. f.) Wall. ex Nees: A Review of Ethnobotany, Phytochemistry, and Pharmacology](https://pubmed.ncbi.nlm.nih.gov/25950015/) - Hossain et al., 2014

A thorough review of the plant's history, chemistry, and pharmacology that catalogues the many diterpenoid and flavonoid compounds behind its reported activities.

* [Physiological Activities of the King of Bitters (Andrographis paniculata): A Review](https://pubmed.ncbi.nlm.nih.gov/37719535/) - Bhaisare et al., 2023

A recent narrative review summarizing antibacterial, antioxidant, antidiabetic, anti-inflammatory, and anticancer activity alongside a concise toxicity profile.

<!-- Note to reader: No directly relevant, topic-specific Andrographis content was located from Rhonda Patrick, Peter Attia, or Andrew Huberman despite web and on-platform searches; the priority slots were therefore filled with Chris Kresser and Life Extension content plus qualifying narrative reviews. -->


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool; a dedicated article for Andrographis paniculata was located. -->

* [Andrographis paniculata](https://grokipedia.com/page/Andrographis_paniculata)

The article provides a broad reference overview of the plant's taxonomy, cultivation, phytochemistry, and traditional and clinical uses.


## Examine

<!-- examine.com was searched directly using the browser tool; a dedicated supplement page for Andrographis paniculata was located. -->

* [Andrographis paniculata](https://examine.com/supplements/andrographis-paniculata/)

Examine's evidence-graded page summarizes the human trial data for common cold, joint pain, and other outcomes, along with dosing and safety caveats.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool; a dedicated answer/article for Andrographis was located. -->

* [Andrographis for Colds, Arthritis and More](https://www.consumerlab.com/answers/andrographis-colds-arthritis/andrographis/)

ConsumerLab reviews the clinical uses, dosing, and safety of Andrographis and, notably, reports independent testing showing many marketed products contain far less active compound than labeled.


## Systematic Reviews

The following systematic reviews and meta-analyses represent the highest-tier synthesized evidence on Andrographis, prioritized by relevance, size, and recency.

* [Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/28783743/) - Hu et al., 2017

Pooling 33 randomized controlled trials (7,175 patients), this is the largest synthesis of respiratory data, finding the herb improved cough and sore throat versus placebo, though the authors flagged generally poor study quality.

* [Safety of Andrographis paniculata: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/33372366/) - Worakunphanich et al., 2021

The most focused safety synthesis to date, quantifying that serious adverse events are very rare while non-serious events (mostly digestive and skin-related) are common, concluding the oral herb is generally safe.

* [Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies](https://pubmed.ncbi.nlm.nih.gov/35153776/) - Shang et al., 2022

An important safety analysis of 262 studies showing that injectable andrographolide derivatives carry a real anaphylaxis risk, whereas oral herbal preparations are essentially safe — a key route-dependent distinction.

* [Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/38612967/) - Iyengar et al., 2024

A meta-analysis of herbal therapies in ulcerative colitis that found Andrographis did not significantly outperform placebo for clinical response or remission, tempering earlier optimism about the herb for bowel inflammation.

* [Exploring the clinical effects of Andrographis paniculata-derived compounds, its extract, or derivatives for the treatment of COVID-19: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40822451/) - Prabhakornritta et al., 2025

Pooling six randomized trials (660 adults), this recent review found no significant effect on fever or cough resolution or on inflammatory markers in mild-to-moderate COVID-19, illustrating the gap between mechanistic promise and clinical results.


## Mechanism of Action

Andrographis acts largely through andrographolide, a labdane diterpenoid lactone (a plant compound built on a two-ring carbon skeleton). Its central and best-supported action is inhibition of NF-κB (nuclear factor kappa B, a master switch that turns on genes driving inflammation). By blocking this pathway, andrographolide reduces production of inflammatory messengers such as TNF-α (tumor necrosis factor alpha, a pro-inflammatory signaling protein), IL-6 (interleukin-6, another inflammatory signal), and various prostaglandins.

Several complementary mechanisms are proposed:

* **Antioxidant defense:** Andrographolide activates Nrf2 (a protein that switches on the cell's own antioxidant genes), raising internal defenses against oxidative stress.

* **Inflammasome suppression:** It dampens the NLRP3 inflammasome (a cellular alarm complex that triggers inflammatory bursts), a pathway increasingly linked to age-related disease.

* **Immune modulation:** Rather than simply stimulating immunity, the herb appears to balance it — increasing lymphocyte (a type of white blood cell) activity and antibody responses in some settings while restraining overactive inflammation in others.

* **Antiviral and antibacterial action:** In laboratory studies andrographolide interferes with viral replication and bacterial signaling, supporting its traditional use in infection.

Competing interpretations exist. Some researchers argue the immune-balancing framing is oversimplified, noting that many effects are demonstrated only at high laboratory concentrations that oral dosing may not reach in human tissue. Others counter that clinical symptom benefits in respiratory infection imply meaningful activity despite modest blood levels.

As a compound, andrographolide has a short half-life (roughly 2 hours) and poor oral bioavailability owing to rapid metabolism. It is cleared mainly by sulfation and glucuronidation (attachment of small molecules that make it water-soluble for excretion) and can influence several liver enzymes of the CYP (cytochrome P450, the main family of drug-metabolizing enzymes) system, including CYP1A2, CYP2C9, and CYP3A4, as well as the P-glycoprotein drug transporter.


## Historical Context & Evolution

Andrographis has a documented history of medicinal use stretching back centuries in Ayurvedic and traditional Chinese medicine, where the bitter aerial parts were used for fevers, "heat" conditions, liver complaints, digestive upset, and infectious illness. In India it is a classic remedy for liver disorders and fevers; in China (as Chuan Xin Lian) it features in formulas for sore throat and respiratory infection.

Its move into modern health optimization began in the late twentieth century, when Scandinavian and Thai researchers standardized extracts and ran the first controlled trials for the common cold. A widely cited finding was that a fixed Andrographis extract, taken preventively over a winter, roughly halved the number of colds compared with placebo — a headline result that drove commercial interest.

Historical laboratory research also raised safety questions that remain relevant. Mid-twentieth-century and later animal studies reported that very high doses could impair male fertility and, separately, that the plant had contraceptive-like effects, echoing a traditional reputation as an anti-fertility agent. These findings were later probed in human and follow-up animal work with mixed results, and the current standing is unsettled rather than "disproven": ordinary supplement doses have not shown clear reproductive harm in people, but the animal signal has not been fully explained.

Scientific opinion continues to evolve. Early enthusiasm for respiratory benefit has been partly tempered by later reviews highlighting weak trial quality, while newer interest in the herb's anti-inflammatory and metabolic actions has opened fresh research directions on either side of the ledger.


## Expected Benefits

Benefits below are grouped by the strength of supporting evidence. A dedicated search of clinical trials, meta-analyses, and expert sources was performed to capture the herb's full benefit profile before writing this section.


### High 🟩 🟩 🟩

#### Relief of Upper Respiratory Tract Infection Symptoms

The best-supported use is easing the symptoms of colds and other upper respiratory tract infections (infections of the nose, throat, and airways). A meta-analysis of 33 randomized controlled trials (RCTs — studies that randomly assign participants to treatment or placebo) covering 7,175 patients found the herb reduced cough and sore throat and shortened time to recovery, likely through combined antiviral and anti-inflammatory action. The main limitation is that most contributing trials were methodologically weak, so the effect size is uncertain even though the direction is consistent.

**Magnitude:** Versus placebo, cough improved by a standardized mean difference (SMD, a way of expressing effect size across different scales) of −0.39 (95% confidence interval, or CI, the plausible range for the true effect: −0.67 to −0.10) and sore throat by −1.13 (95% CI −1.37 to −0.89).


### Medium 🟩 🟩

#### Prevention of Common Colds

Beyond treating an active cold, taking Andrographis preventively through cold season appears to lower how often colds occur. Several early double-blind trials of standardized extracts reported meaningfully fewer infections in those taking the herb, consistent with its immune-balancing mechanism. Evidence is graded Medium because the supporting trials are older, relatively small, and used specific proprietary extracts that may not represent all products.

**Magnitude:** In preventive dosing over about three months, the proportion of people catching a cold fell by roughly half (on the order of 30% with the herb versus 60% with placebo in the most-cited trial).


#### Knee Osteoarthritis Pain Relief

Standardized Andrographis extracts (often the branded ParActin form) have reduced knee pain and stiffness in osteoarthritis, the wear-related joint disease. The proposed mechanism is suppression of joint inflammation via NF-κB blockade. Several placebo-controlled trials support a benefit, though sample sizes are modest and many were industry-sponsored, which warrants some caution.

**Magnitude:** In 90-day placebo-controlled trials, knee pain and function scores improved significantly more than placebo, with reductions on the order of 30–50% from baseline in the better studies.


### Low 🟩

#### Rheumatoid Arthritis Symptom Relief

In rheumatoid arthritis (an autoimmune disease attacking the joints), a small placebo-controlled trial of a standardized extract added to usual care reported fewer tender and swollen joints and less fatigue. The effect fits the herb's anti-inflammatory profile, but the evidence rests on a single small study, so confidence is low.

**Magnitude:** Over 14 weeks, tender/swollen joint counts and fatigue improved significantly versus placebo (roughly a 20–30% greater reduction than the control group) in one 60-patient trial.


#### Ulcerative Colitis Improvement ⚠️ Conflicted

For ulcerative colitis (an inflammatory disease of the large bowel), a purified Andrographis extract showed early promise in mid-stage trials but did not hold up in later pooled analysis. The evidence is directly conflicted: an earlier phase-2 trial suggested benefit, while a large phase-3 program was terminated and a 2024 meta-analysis found no significant advantage over placebo.

**Magnitude:** A phase-2 trial reported clinical response around 60% versus 40% for placebo at 8 weeks, but pooled analysis found no significant difference in response (relative risk 0.95) or remission (relative risk 1.31).


#### Glycemic and Metabolic Support

Small human studies and abundant animal data suggest Andrographis may modestly improve blood-sugar handling, possibly by increasing GLP-1 (glucagon-like peptide-1, a gut hormone that stimulates insulin release) and improving insulin sensitivity. This is relevant to longevity given the central role of metabolic health, but human evidence is limited to small, short trials.

**Magnitude:** Small trials report modest reductions in fasting insulin and insulin-resistance scores (on the order of 10–20%) rather than large changes in blood sugar.


### Speculative 🟨

#### Reduced Chronic ("Inflammaging") Inflammation for Longevity

By dampening NF-κB and the NLRP3 inflammasome, Andrographis could in theory lower the smoldering, low-grade inflammation that accompanies aging and drives many age-related diseases. This longevity-relevant rationale is strong mechanistically but rests largely on laboratory and animal work, with human trials showing inconsistent changes in inflammatory markers.


#### Anticancer Activity

Andrographolide slows the growth of many cancer cell types in the laboratory and in animal models, acting on cell-death and inflammation pathways. No controlled human trials establish a cancer-prevention or treatment benefit, so this remains a mechanistic and preclinical signal only.


#### Liver Protection

Traditional use as a liver tonic is echoed by animal studies where andrographolide protects against chemical and fatty-liver injury. Human evidence is sparse and indirect, and — as noted in the risks section — the herb can occasionally raise liver enzymes, so any protective role is unproven in people.


#### Neuroprotection and Multiple Sclerosis Support

In small trials in multiple sclerosis (an autoimmune disease of the nervous system), andrographolide reduced fatigue and was studied for its effect on brain tissue loss, and laboratory work suggests broader nerve-protective activity. The human data are preliminary, drawn from very small studies, and not yet confirmed.


## Benefit-Modifying Factors

* **Genetic polymorphisms:** Variation in CYP2C9 and CYP3A4 (liver enzymes that metabolize andrographolide) and in the P-glycoprotein transporter may alter how much active compound reaches the tissues, potentially shifting both benefit and drug-interaction risk between individuals.

* **Baseline inflammation and biomarkers:** People starting with higher baseline inflammation (for example elevated hs-CRP, a sensitive marker of body-wide inflammation) or higher fasting insulin may have more room to benefit from an anti-inflammatory, insulin-sensitizing herb than those already in optimal ranges.

* **Sex-based differences:** Most respiratory trials enrolled both sexes without clear divergence, but the historical male-fertility signal means benefit-versus-risk calculations differ for men considering long-term high-dose use.

* **Pre-existing health conditions:** Those with inflammatory or autoimmune joint and bowel conditions are the populations in whom benefits have been most studied; conversely, people with autoimmune disease driven by immune overactivity may respond unpredictably given the herb's immune-balancing effects.

* **Age-related considerations:** Older adults — the group most affected by "inflammaging," osteoarthritis, and frequent infections — are plausibly the best-positioned to benefit, though they also tend to take more interacting medications and clear compounds more slowly.


## Potential Risks & Side Effects

Risks below are grouped by strength of evidence. A dedicated review of trial safety data, pharmacovigilance analyses, and drug-reference sources was performed to capture the full side-effect profile.


### High 🟥 🟥 🟥

#### Gastrointestinal Disturbance

The most common adverse effects are digestive: nausea, diarrhea, loss of appetite, and abdominal discomfort, consistent with the herb's intense bitterness and effect on the gut. These are typically mild and resolve on stopping. A safety meta-analysis classed non-serious events as "very common."

**Magnitude:** Pooled non-serious adverse events occurred at roughly 100 per 1,000 patients (about 10%) in randomized trials, with digestive complaints among the most frequent.


#### Allergic and Skin Reactions

Skin and hypersensitivity reactions — rash, itching, and hives (urticaria, raised itchy welts) — are among the most frequently reported non-serious effects. They generally resolve after discontinuation but signal that some people are sensitive to the herb.

**Magnitude:** Not quantified in available studies.


### Medium 🟥 🟥

#### Anaphylaxis ⚠️ Conflicted

Severe, life-threatening allergic reactions (anaphylaxis, a rapid whole-body allergic collapse) have been reported, but the evidence is route-dependent and therefore conflicted. Serious reactions cluster almost entirely around injectable andrographolide derivatives used in some countries, not the oral herb, which shows a very low serious-event rate.

**Magnitude:** With injectable derivatives, one review documented 55 cases of anaphylactic shock and several deaths; by contrast, serious adverse events from oral herbal preparations pooled to about 0.02 per 1,000 patients.


#### Additive Blood Pressure Lowering

Andrographis extracts can relax blood vessels and modestly lower blood pressure. On its own this is usually minor, but combined with blood-pressure medication or other hypotensive agents it can contribute to dizziness or excessive lowering, especially in older adults.

**Magnitude:** Not quantified in available studies.


### Low 🟥

#### Liver Enzyme Elevation

Although promoted as a liver-protective herb, Andrographis has occasionally been linked to mild elevations in liver enzymes, signaling low-grade liver stress. Reports are infrequent and generally reversible, and a causal role is not firmly established for standardized oral products.

**Magnitude:** In COVID-19 trials, mild liver-enzyme elevations were the main adverse events and resolved without severe complications; precise incidence is not well quantified.


#### Additive Blood-Sugar Lowering

Because the herb can nudge blood sugar downward, combining it with diabetes medication or other glucose-lowering agents raises a theoretical risk of hypoglycemia (blood sugar falling too low). Evidence is limited to small trials and mechanism.

**Magnitude:** Not quantified in available studies.


#### Reduced Male Fertility ⚠️ Conflicted

High doses impaired sperm quality and testicular structure in some animal studies, and the plant has a traditional anti-fertility reputation. The evidence is conflicted: several follow-up animal studies and limited human data at ordinary doses did not confirm harm, leaving the signal unresolved.

**Magnitude:** Not quantified in available studies.


### Speculative 🟨

#### Autoimmune Overstimulation

Because Andrographis can activate parts of the immune system, there is a theoretical concern it could aggravate autoimmune conditions or interfere with immune-suppressing therapy. This is speculative and somewhat paradoxical, since the herb has also been trialed as an anti-inflammatory in autoimmune disease.


#### Pregnancy Loss (Abortifacient Potential)

Traditional use and some animal data suggest the herb may threaten pregnancy or act against implantation. On this precautionary basis, and absent safety data, use in pregnancy is generally avoided; the human risk is unquantified.


#### Increased Bleeding Risk

Andrographolide can reduce platelet clumping in laboratory studies, raising a theoretical bleeding risk, particularly around surgery or alongside blood-thinning drugs. No clinical bleeding events are well documented, so this remains speculative.


## Risk-Modifying Factors

* **Genetic polymorphisms:** Individuals with reduced-function CYP2C9 or CYP3A4 variants may accumulate higher andrographolide levels, potentially amplifying both side effects and interactions with co-administered medications.

* **Baseline biomarkers:** Pre-existing elevations in liver enzymes or a tendency to low blood pressure or low blood sugar identify people in whom the herb's hepatic, hypotensive, or glucose-lowering effects are more likely to cross into harm.

* **Sex-based differences:** The reproductive-toxicity signal is specific to males, making men — particularly those trying to conceive — the group for whom this risk weighs heaviest.

* **Pre-existing health conditions:** Autoimmune disease, bleeding disorders, gallbladder obstruction (the herb stimulates bile), and pregnancy each raise the risk profile and are relative or absolute reasons for caution.

* **Age-related considerations:** Older adults often take multiple medications (blood thinners, blood-pressure and diabetes drugs) that interact additively with Andrographis, and slower drug clearance can heighten exposure.


## Key Interactions & Contraindications

* **Anticoagulant and antiplatelet drugs:** Warfarin, direct oral anticoagulants, aspirin, and clopidogrel — **caution/monitor.** Andrographolide's antiplatelet activity may add to bleeding risk. Mitigation: avoid around surgery and monitor for bruising or bleeding.

* **Antihypertensive drugs:** ACE inhibitors (angiotensin-converting enzyme inhibitors, which relax blood vessels), calcium channel blockers, and diuretics — **caution.** Additive blood-pressure lowering may cause dizziness. Mitigation: monitor blood pressure when starting.

* **Antidiabetic drugs:** Metformin, sulfonylureas (glipizide, glyburide), and insulin — **caution/monitor.** Additive glucose lowering may risk hypoglycemia; a pharmacokinetic study also paired the herb with metformin. Mitigation: monitor blood sugar and watch for low-glucose symptoms.

* **Immunosuppressants:** Cyclosporine, tacrolimus, and corticosteroids — **caution.** The herb's immune-activating effects could theoretically oppose immunosuppression (for example after organ transplant). Mitigation: transplant recipients should avoid it.

* **Over-the-counter medications:** Nonsteroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen) may add to both antiplatelet and gastrointestinal effects — **monitor.** Other OTC (over-the-counter) cold remedies overlap in purpose but pose no specific danger.

* **CYP-metabolized drugs:** Because andrographolide can modulate CYP1A2, CYP2C9, and CYP3A4 and the P-glycoprotein transporter, blood levels of drugs cleared by these routes (many statins, some blood thinners, certain immune drugs) could shift — **caution.** Mitigation: separate timing and monitor where a narrow-therapeutic-window drug is involved.

* **Supplements with additive effects:** Immune-active herbs (echinacea, elderberry), blood-pressure-lowering supplements (garlic, CoQ10), glucose-lowering supplements (berberine, cinnamon), and antiplatelet supplements (ginkgo, high-dose fish oil, garlic) can each compound the herb's corresponding effect — **monitor** for excessive lowering or bleeding.

* **Other interventions:** Overlap with other anti-inflammatory botanicals (curcumin, boswellia) is generally complementary but can amplify gastrointestinal upset.

* **Populations who should avoid it:** Pregnant or breastfeeding women (potential pregnancy loss); people with known Andrographis or Acanthaceae-family allergy (anaphylaxis risk); organ-transplant recipients and others on essential immunosuppression; those with active bleeding disorders or within roughly 2 weeks of scheduled surgery; and people with gallbladder duct obstruction.


## Risk Mitigation Strategies

* **Start low and use short courses:** Begin at the low end of the dose range and use time-limited courses (for example during an acute cold or for a defined preventive block) rather than open-ended daily use, reducing cumulative exposure that underlies most theoretical risks.

* **Take with food:** Dosing with meals blunts the digestive upset that is the most common side effect and softens the herb's bitterness, improving tolerability.

* **Screen and monitor for interactions:** Before starting, review medications for blood thinners, blood-pressure drugs, diabetes drugs, and immunosuppressants; where these overlap, monitor blood pressure, blood sugar, or bleeding signs as relevant to prevent additive harm.

* **Pause around surgery:** Stop the herb at least 1–2 weeks before any planned surgery or dental procedure to avoid its potential antiplatelet, bleeding-related effect.

* **Check liver enzymes with prolonged use:** For courses beyond a few weeks, obtain baseline and periodic liver-enzyme testing (for example at 4–8 weeks) to catch the uncommon liver-stress signal early.

* **Avoid in defined high-risk groups:** Exclude use in pregnancy, in men actively trying to conceive (given the unresolved fertility signal), and in transplant recipients, sidestepping the risks least worth taking.

* **Choose oral, avoid injectables:** Use only oral standardized herbal preparations, which carry a very low serious-event rate, and avoid injectable andrographolide derivatives, which account for essentially all documented anaphylaxis and deaths.


## Therapeutic Protocol

* **Standard dose (acute infection):** Leading practitioners and clinical trials commonly use standardized extracts supplying roughly 60 mg or more of andrographolide daily, often as ~400 mg of a standardized extract taken two to three times per day, started as early as possible in an illness (within the first 36–48 hours) for best effect.

* **Standard dose (joint or preventive use):** For osteoarthritis and general anti-inflammatory use, branded standardized extracts (such as ParActin) are typically dosed around 300 mg per day; preventive cold-season regimens have used lower daily doses of standardized extract over several weeks.

* **Competing approaches:** A symptom-focused, short-course approach (used at the first sign of infection, favored in Western herbal and integrative practice) contrasts with a preventive daily-dosing approach through cold season (popularized by the Scandinavian standardized-extract trials); neither is established as superior, and both are presented as legitimate options.

* **Expert and product lineage:** The preventive respiratory approach traces to the Swedish Herbal Institute's fixed-combination extract (Kan Jang), while the joint-and-inflammation approach centers on the ParActin standardized extract developed by HP Ingredients.

* **Best time of day:** Doses are usually spread across the day with meals; there is no strong circadian rationale, and food timing (to reduce bitterness and stomach upset) matters more than clock time.

* **Half-life and dosing frequency:** Because andrographolide has a short half-life of roughly 2 hours, split dosing two to three times daily is preferred over a single daily dose to maintain exposure.

* **Single versus split dosing:** Split dosing is standard; single large doses are neither more effective nor better tolerated given rapid clearance.

* **Genetic considerations:** No validated pharmacogenetic dosing exists, but reduced-function CYP2C9 or CYP3A4 variants may warrant conservative dosing because of slower breakdown of andrographolide.

* **Sex-based considerations:** Men concerned about fertility may prefer short courses over continuous long-term use given the unresolved reproductive signal.

* **Age considerations:** Older adults should start at the low end and account for interacting medications and slower clearance.

* **Baseline biomarkers:** Baseline liver enzymes, blood pressure, and blood sugar help individualize dosing and flag those who need closer monitoring.

* **Pre-existing conditions:** Autoimmune disease, bleeding tendency, and gallbladder disease should steer dosing decisions and, in some cases, argue against use.


## Discontinuation & Cycling

* **Lifelong versus short-term:** Andrographis is best regarded as a short-term or cyclical intervention (for acute infections or defined preventive blocks) rather than an indefinite lifelong supplement, since its strongest evidence is for time-limited use.

* **Withdrawal effects:** No withdrawal syndrome or dependence has been described; the herb can be stopped abruptly without rebound effects.

* **Tapering:** No tapering protocol is required given the absence of withdrawal effects.

* **Cycling:** Cycling is commonly practiced — for example short acute courses, seasonal preventive blocks, or on/off patterns — to limit continuous immune stimulation and cumulative exposure, though no formal cycling schedule has been validated in trials.

* **Practical pattern:** A typical approach is a several-day course at illness onset, or a preventive block through the highest-risk weeks of cold season, followed by a break.


## Sourcing and Quality

* **Standardization to andrographolide:** The most important quality marker is standardization to a stated andrographolide content (commonly 10–30%); unstandardized "whole herb" powders vary widely and may be under-dosed.

* **Third-party testing:** Independent testing is essential — ConsumerLab has reported that many marketed Andrographis products contain far less active compound than labeled, and some none at all — so verified certificates of analysis and third-party seals matter.

* **Species authentication and contaminants:** Look for confirmation of correct species (*Andrographis paniculata*, not adulterants) and testing for heavy metals and microbial contamination, which affect botanical products generally.

* **Reputable formulations:** Well-characterized branded extracts such as ParActin and the Kan Jang fixed combination have the most clinical backing; reputable supplement brands that publish testing data are preferable to unbranded bulk powders.

* **Form and route:** Choose oral capsules or tablets of standardized extract; avoid injectable andrographolide derivatives, which are the source of the serious safety signals.


## Practical Considerations

* **Time to effect:** For an active cold, symptom relief typically appears within 1–2 days; preventive benefits build over weeks of consistent use; joint-pain improvements generally take several weeks to a few months.

* **Common pitfalls:** Starting too late in an infection (missing the early window), using low-quality or under-dosed products, being deterred by the strong bitter taste, and taking the herb continuously without breaks are the most frequent mistakes.

* **Regulatory status:** In the United States, Andrographis is sold as a dietary supplement and is not an FDA-approved drug; it is used within traditional-medicine frameworks elsewhere, and injectable andrographolide derivatives are regulated medicines in some countries but not marketed in the US.

* **Cost and accessibility:** Standardized Andrographis is inexpensive and widely available, so cost and access are not meaningful barriers.

* **Taste and formulation:** The intense bitterness (the source of the "King of Bitters" name) makes capsules preferable to powders or teas for most users.


## Interaction with Foundational Habits

* **Sleep:** The interaction is largely neutral — Andrographis is not a stimulant and is unlikely to disrupt sleep; any indirect benefit would come from reducing the inflammation and infection symptoms that impair rest. It can be taken in the evening with a meal without expected sleep interference.

* **Nutrition:** The interaction is direct and generally favorable — the herb's bitterness stimulates digestive secretions and bile flow, and taking it with food both improves tolerance and aligns with traditional use as a digestive bitter; no specific nutrient depletion is established, and no special diet is required.

* **Exercise:** The interaction is potentially blunting but speculative — as with other strong anti-inflammatory and antioxidant compounds, there is a theoretical concern that heavy dosing around training could dampen the beneficial inflammatory signals that drive adaptation. A practical precaution is to separate dosing from the immediate post-workout window if muscle or strength gains are a priority.

* **Stress management:** The interaction is indirect and mild — Andrographis is sometimes grouped with adaptogenic herbs and may modestly influence stress-related inflammation, but robust human data on cortisol or the stress response are lacking, so it should not be relied on as a stress-management tool.


## Monitoring Protocol & Defining Success

Before starting, a baseline assessment establishes reference values for the organs and pathways most likely to be affected — chiefly the liver, blood pressure, and blood sugar — so that any later change can be interpreted. Ongoing monitoring is light for short courses but more structured for prolonged or preventive use: check liver enzymes at roughly 4–8 weeks after starting continuous use, then every 6–12 months, and monitor blood pressure and blood sugar more often in people on interacting medications.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| ALT | ~10–25 U/L | Detects liver stress from prolonged use | Alanine aminotransferase, a liver enzyme; conventional labs flag only >40–55 U/L; fasting not required; pair with AST |
| AST | ~10–25 U/L | Complements ALT for liver monitoring | Aspartate aminotransferase, a liver enzyme; mildly raised by intense exercise; interpret alongside ALT |
| hs-CRP (high-sensitivity C-reactive protein) | <1.0 mg/L (ideally <0.5) | Tracks whether inflammation is falling | Avoid testing during active infection, which transiently elevates it |
| Fasting glucose | 70–85 mg/dL | Watches for additive blood-sugar lowering | Requires overnight fast; check more often if on diabetes drugs |
| Systolic blood pressure | 110–120 mmHg | Watches for additive blood-pressure lowering | Measure seated after rest; relevant if on antihypertensives |
| Platelet function / bleeding signs | No easy bruising or bleeding | Flags the theoretical antiplatelet effect | Clinical observation rather than a routine lab; relevant around surgery |

* Baseline testing (above) should be completed before beginning prolonged or preventive use, not only inferred from later results.

* Ongoing testing cadence: liver enzymes at about 4–8 weeks of continuous use, then every 6–12 months; blood pressure and blood sugar at 1–2 weeks after starting if on interacting drugs, then periodically.

Qualitative markers to track:

* Frequency and severity of colds and respiratory infections over a season
* Energy levels and post-illness recovery time
* Joint comfort and stiffness (for those using it for joint pain)
* Digestive comfort (appetite, nausea, bowel habits)
* Any new rash, itching, or hives, which warrant stopping the herb


## Emerging Research

* **Metabolic and blood-pressure trials in obesity:** Two newly registered controlled studies from an Indonesian university are comparing Andrographis (Sambiloto) against brisk-walking exercise for blood glucose ([NCT06520501](https://clinicaltrials.gov/study/NCT06520501), not-yet-recruiting, ~30 participants) and blood pressure ([NCT06520527](https://clinicaltrials.gov/study/NCT06520527), not-yet-recruiting, ~30 participants) in people with obesity — directly probing the herb's longevity-relevant metabolic effects.

* **Large antiviral prevention trial:** A phase-3 Thai study ([NCT05019326](https://clinicaltrials.gov/study/NCT05019326), ~3,060 participants) compared *Andrographis paniculata* against another botanical and control for preventing progression in early COVID-19, one of the largest Andrographis trials attempted, though its status is currently listed as unknown.

* **Joint-structure imaging trial:** A completed 336-day study of the ParActin extract used magnetic-resonance imaging to assess joint-space narrowing in knee osteoarthritis ([NCT04833946](https://clinicaltrials.gov/study/NCT04833946), ~80 participants), moving beyond symptom scores toward structural disease progression.

* **Respiratory evidence quality:** Future respiratory research could strengthen or weaken the case depending on whether large, well-designed trials confirm the symptom benefits suggested by weaker studies; the largest meta-analysis to date ([Hu et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28783743/)) explicitly called for better trials.

* **Inflammation biomarker uncertainty:** Emerging synthesis is mixed on whether the herb measurably lowers inflammation in people — a recent COVID-19 meta-analysis ([Prabhakornritta et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40822451/)) found no significant change in inflammatory markers, a finding that, if repeated, would weaken the "inflammaging" longevity rationale.

* **Unresolved reproductive safety:** Better human data on male fertility remain a key open question; resolving the animal-versus-human discrepancy could meaningfully shift the risk profile for long-term users.


## Conclusion

Andrographis is a bitter medicinal herb with a long traditional history and a modern reputation built mainly on easing colds and other respiratory infections. Its most consistent human evidence points to faster relief of cough and sore throat and, with preventive use, fewer colds through the season, likely reflecting a combination of calming inflammation and balancing the immune response. Beyond infection, the herb shows encouraging but weaker signals for joint pain and blood-sugar handling, and a mechanistically appealing but still-unproven role in lowering the chronic, low-grade inflammation tied to aging.

The overall evidence base is uneven. Respiratory findings rest on many trials of generally poor quality, several other uses come from single small studies, and results for bowel inflammation and inflammatory markers have been disappointing or conflicting. Safety is reassuring for the oral herb, whose serious reactions are rare, though digestive upset and allergic skin reactions are common, and unresolved questions linger around male fertility, pregnancy, and additive effects with blood thinners, blood-pressure, and diabetes treatments; the severe reactions on record trace almost entirely to injectable forms, not the supplement. For those weighing it as part of a long-term health strategy, Andrographis reads as a modestly supported, low-cost option whose promise for healthy aging outruns the current proof.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**